Exploring New Combination Therapy for Crohn's Disease
Study Overview:
This study focuses on evaluating the effectiveness of a new drug, JNJ-78934804, in treating individuals with moderately to severely active Crohn's Disease. The trial, conducted over 48 weeks, compares JNJ-78934804's efficacy against two established medications, guselkumab and golimumab.
Design:
The study is a Phase 2b clinical trial. Participants are randomly assigned to receive either JNJ-78934804, guselkumab, golimumab, or a placebo in a double-blind setting. This means neither the participants nor the researchers know who is receiving which treatment, ensuring unbiased results.
Importance:
This study could pave the way for new, more effective treatment combinations for those suffering from Crohn's Disease, potentially improving the quality of life for many.
Participation:
Those with moderately to severely active Crohn's Disease interested in exploring new treatment avenues may consider participating in this groundbreaking study.
Who Can Participate in the Crohn's Disease Study?
Who can join:
- Individuals diagnosed with moderate to severe Crohn's disease for at least 3 months.
- Those who haven't had success with at least one biologic treatment for Crohn's disease, whether it didn't work well, stopped working, or caused adverse reactions.
Who cannot join:
- Anyone who has had a part of their bowel surgically removed in the last 6 months.
- Those who have had any major abdominal or other significant surgery in the last 3 months.
- Individuals with a draining stoma or ostomy (an opening created for waste removal).
- Women who are currently pregnant or breastfeeding.
If you fit the criteria for joining and are interested in exploring new treatment options, this study might be a suitable opportunity for you!